![Blaise Lippa](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Blaise Lippa
Direttore Tecnico/Scientifico/R&S presso
MORC HOLD
Profilo
Blaise Lippa is currently the Chief Scientific Officer at Morphic Therapeutic, Inc. since 2015 and at Morphic Holding, Inc. since 2022.
Previously, Blaise worked as the Senior Director-Medicinal Chemistry at Cubist Pharmaceuticals LLC.
Blaise holds a doctorate degree from Stanford University and an undergraduate degree from the University of Michigan.
Posizioni attive di Blaise Lippa
| Società | Posizione | Inizio |
|---|---|---|
| MORC HOLD | Direttore Tecnico/Scientifico/R&S | 12/05/2022 |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Direttore Tecnico/Scientifico/R&S | 01/06/2015 |
Precedenti posizioni note di Blaise Lippa
| Società | Posizione | Fine |
|---|---|---|
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | - |
Formazione di Blaise Lippa
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
8
Relazioni di 1° grado
5
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Health Technology |
Morphic Holding, Inc.
 Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
